Abstract
Therapies that target molecular pathways do not provide uniform benefits for all patients at present. New transformative therapies for autoimmune and inflammatory diseases require greater molecular understanding of patient subsets and the ability to personalize targeted therapies for each subset.
MeSH terms
-
Antineoplastic Agents / economics
-
Antineoplastic Agents / therapeutic use
-
Autoimmune Diseases / genetics
-
Autoimmune Diseases / immunology
-
Autoimmune Diseases / therapy*
-
Genetic Heterogeneity
-
Humans
-
Immunosuppressive Agents / economics
-
Immunosuppressive Agents / therapeutic use
-
Inflammation / genetics
-
Inflammation / immunology
-
Inflammation / therapy*
-
Molecular Targeted Therapy*
-
Neoplasms / genetics
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Precision Medicine*
Substances
-
Antineoplastic Agents
-
Immunosuppressive Agents